Genetic alterations in 47 patients with a novel myelodysplastic syndrome diagnosis at a single center

Zhao,Pan; Qin,Jiayue; Liu,Weiyi; Quan,Richeng; Xiao,Haiyan; Liu,Chi; Li,Liu; Lv,Yan; Zhu,Qianze; Wang,Hongzhi; Guo,Xiaoqing; Wang,Juan; Hu,Xiaomei

doi:10.3892/ol.2019.10853

Genetic alterations in 47 patients with a novel myelodysplastic syndrome diagnosis at a single center

Authors:
- Pan Zhao
- Jiayue Qin
- Weiyi Liu
- Richeng Quan
- Haiyan Xiao
- Chi Liu
- Liu Li
- Yan Lv
- Qianze Zhu
- Hongzhi Wang
- Xiaoqing Guo
- Juan Wang
- Xiaomei Hu
View Affiliations

Affiliations: Department of Hematology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, P.R. China, Annoroad Gene Technology Co., Ltd., Beijing 100176, P.R. China
Published online on: September 12, 2019 https://doi.org/10.3892/ol.2019.10853
Pages: 5077-5084
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

At least one mutation is present in 70‑80% of patients with myelodysplastic syndrome (MDS). Genetic alterations and other molecular biological markers have been included in the diagnostic and treatment guidelines for MDS. The aim of the present study was to analyze the association between genetic alterations and clinicopathological features among 47 Chinese patients with a novel diagnosis of MDS using a next‑generation sequencing approach. The results indicated that from the 47 patients, 66.0% had genetic alterations. Furthermore, seven genes, U2 small nuclear RNA auxiliary factor 1 (23.4%), splicing factor 3b subunit (12.8%), ASXL transcriptional regulator 1 (10.6%), tet methylcytosine dioxygenase 2 (8.5%), BCL6 corepressor (8.5%), TP53 (8.5%) and DNA methyltransferase 3α (6.4%), indicated a higher prevalence of alterations in >5% of patients. Among the 16 (51.6%) patients with ≥2 mutations, 12 (75%) had mutations in different genetic functional groups. Variant allele frequencies in signaling pathways were generally low, suggesting that mutations in the corresponding genes were acquired relatively late during the evolution of the leukemic clones. The mutation prevalence rates of Janus kinase 2 and SH2B adaptor protein 3 were significantly higher in the MDS unclassified group and in the very high‑risk groups with a karyotype as a prognostic indicator, respectively (both P<0.05). The mutation prevalence rates of SET binding protein 1 and enhancer of zeste 2 polycomb repressive complex 2 subunit were significantly higher in the high‑risk group (both P<0.05). In summary, 66.0% of the 47 patients with a novel MDS diagnosis had a genetic mutation as detected by 127‑target gene next‑generation sequencing. The results for the genetic alterations in the present study will supplement the database of patients with MDS in China.

View Figures

View References

1	Della Porta MG, Galli A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, et al: Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 34:3627–3637. 2016. View Article : Google Scholar : PubMed/NCBI
2	Cazzola M and Malcovati L: Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med. 352:536–538. 2005. View Article : Google Scholar : PubMed/NCBI
3	Ades L, Itzykson R and Fenaux P: Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhang L, Padron E and Lancet J: The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes. Leuk Res. 39:6–17. 2015. View Article : Google Scholar : PubMed/NCBI
5	Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, et al: Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 122:3616–3627. 2013. View Article : Google Scholar : PubMed/NCBI
6	Cazzola M, Della Porta MG and Malcovati L: The genetic basis of myelodysplasia and its clinical relevance. Blood. 122:4021–4034. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ogawa S: Genetics of MDS. Blood. 7:1049–1059. 2019. View Article : Google Scholar
8	Tefferi A and Vardiman JW: Myelodysplastic syndromes. N Engl J Med. 361:1872–1885. 2009. View Article : Google Scholar : PubMed/NCBI
9	Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T, et al: Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 28:241–247. 2014. View Article : Google Scholar : PubMed/NCBI
10	McGranahan N and Swanton C: Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell. 168:613–628. 2017. View Article : Google Scholar : PubMed/NCBI
11	Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, et al: Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:60–87. 2017. View Article : Google Scholar : PubMed/NCBI
12	Walter MJ, Shen D, Shao J, Ding L, White BS, Kandoth C, Miller CA, Niu B, McLellan MD, Dees ND, et al: Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 27:1275–1282. 2013. View Article : Google Scholar : PubMed/NCBI
13	Ruffalo M, Husseinzadeh H, Makishima H, Przychodzen B, Ashkar M, Koyuturk M, Maciejewski JP and LaFramboise T: Whole-exome sequencing enhances prognostic classification of myeloid malignancies. J Biomed Inform. 58:104–113. 2015. View Article : Google Scholar : PubMed/NCBI
14	Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, et al: Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 31:727–736. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, et al: Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 42:722–726. 2010. View Article : Google Scholar : PubMed/NCBI
16	Gonzalez Garcia JR and Meza-Espinoza JP: Use of the international system for human cytogenetic nomenclature (ISCN). Blood. 108:3952–3953. 2006. View Article : Google Scholar : PubMed/NCBI
17	Li H and Durbin R: Fast and accurate short read alignment with burrows-wheeler transform. Bioinformatics. 25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
18	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M and DePristo MA: The genome analysis toolkit: A mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
19	Wang K, Li M and Hakonarson H: ANNOVAR: Functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38:e1642010. View Article : Google Scholar : PubMed/NCBI
20	Xu Y, Li Y, Xu Q, Chen Y, Lv N, Jing Y, Dou L, Bo J, Hou G, Guo J, et al: Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing. Oncotarget. 8:82475–82490. 2017.PubMed/NCBI
21	Li B, Liu J, Jia Y, Wang J, Xu Z, Qin T, Shi Z, Song Z, Peng S, Huang H, et al: Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes. Genes Chromosomes Cancer. 57:80–88. 2018. View Article : Google Scholar : PubMed/NCBI
22	Xu F, Wu LY, He Q, Wu D, Zhang Z, Song LX, Zhao YS, Su JY, Zhou LY, Guo J, et al: Exploration of the role of gene mutations in myelodysplastic syndromes through a sequencing design involving a small number of target genes. Sci Rep. 7:431132017. View Article : Google Scholar : PubMed/NCBI
23	Wu L, Song L, Xu L, Chang C, Xu F, Wu D, He Q, Su J, Zhou L, Xiao C, et al: Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 chinese patients with myelodysplastic syndromes. Tumour Biol. 37:4633–4640. 2016. View Article : Google Scholar : PubMed/NCBI
24	Inoue D, Kitaura J, Matsui H, Hou HA, Chou WC, Nagamachi A, Kawabata KC, Togami K, Nagase R, Horikawa S, et al: SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS. Leukemia. 29:847–857. 2015. View Article : Google Scholar : PubMed/NCBI
25	Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016. View Article : Google Scholar : PubMed/NCBI
26	Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, et al: Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med. 210:2627–2639. 2013. View Article : Google Scholar : PubMed/NCBI